LON:SUMM Summit Therapeutics (SUMM) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Summit Therapeutics Stock (LON:SUMM) Get Summit Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume280,318 shsAverage Volume382,504 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom. Read More Receive SUMM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SUMM Stock News HeadlinesSummit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in ChinaSeptember 18, 2025 | finance.yahoo.comBarclays Initiates Coverage of Summit Therapeutics (SMMT) with Underweight RecommendationSeptember 17, 2025 | msn.comAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.October 2 at 2:00 AM | Porter & Company (Ad)Summit Therapeutics Stock Draws Cautious Retail Mood After Barclays ‘Underweight’ Call: ‘Added To The Biotech Graveyard’September 17, 2025 | msn.comSummit Therapeutics initiated with an Underweight at BarclaysSeptember 16, 2025 | msn.comSummit Therapeutics director Zanganeh buys shares worth $5.9mSeptember 12, 2025 | investing.comDuggan buys Summit Therapeutics (SMMT) shares worth $5.9mSeptember 12, 2025 | investing.comGuggenheim Initiates Summit Therapeutics (SMMT) With a Buy RatingSeptember 10, 2025 | msn.comSee More Headlines SUMM Stock Analysis - Frequently Asked Questions How were Summit Therapeutics' earnings last quarter? Summit Therapeutics PLC (LON:SUMM) posted its earnings results on Wednesday, June, 12th. The company reported ($3.00) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.00) by $1.00. How do I buy shares of Summit Therapeutics? Shares of SUMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Summit Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Summit Therapeutics investors own include Summit Therapeutics (SMMT), American Airlines Group (AAL), Acadia Healthcare (ACHC), Academy Sports and Outdoors (ASO), Diana Shipping (DSX), 2570 (JLF.L) (JLF) and National Fuel Gas (NFG). Company Calendar Last Earnings6/12/2019Today10/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drugs - Generic Sub-IndustryN/A Current SymbolLON:SUMM CIKN/A Webwww.summitplc.com Phone+44-1235-443939FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (LON:SUMM) was last updated on 10/2/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThis Biotech has a clinical approach that intrigues investorsThis biotech is gearing up for Phase 2 trials with a strategy to unlock multiple approvals from one study. ...i2i Marketing Group, LLC | SponsoredChina’s message to TrumpPorter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredExpert Alert: Massive Bubble Could Crash Your WealthOn July 4th, Trump signed the “One Big Beautiful Bill,” adding $3.4 trillion to the national debt — and pushin...American Alternative | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.